公开(公告)号：EP3095781B1

公开(公告)日：2018-10-03

申请号：EP15737185.7

申请日：2015-01-13

申请人： Astellas Pharma Inc.

发明人： MATSUMOTO, Shunichiro ,  SHIMIZU, Takafumi ,  SAITO, Tomoyuki ,  KANAYAMA, Takatoshi ,  TANAKA, Hiroaki ,  MORI, Chiharu ,  YOKOYAMA, Kazuhiro ,  MATSUI, Shigeo

IPC分类号： C07D209/16 ,  A61K31/4045 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61P13/10 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

CPC分类号： C07D209/16 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

摘要： [Problem] To provide a compound useful as a MT 1 and/or MT 2 receptor agonist. [Solution] The present inventors have studied on MT 1 and/or MT 2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT 1 and/or MT 2 receptor agonistic activity and has a low ability of migrating into the central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT 1 and/or MT 2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.

公开(公告)号：EP3095781A1

公开(公告)日：2016-11-23

申请号：EP15737185.7

申请日：2015-01-13

申请人： Astellas Pharma Inc.

发明人： MATSUMOTO, Shunichiro ,  SHIMIZU, Takafumi ,  SAITO, Tomoyuki ,  KANAYAMA, Takatoshi ,  TANAKA, Hiroaki ,  MORI, Chiharu ,  YOKOYAMA, Kazuhiro ,  MATSUI, Shigeo

IPC分类号： C07D209/16 ,  A61K31/4045 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61P13/10 ,  A61P43/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

CPC分类号： C07D209/16 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

摘要： [Problem] To provide a compound useful as a MT 1 and/or MT 2 receptor agonist. [Solution] The present inventors have studied on MT 1 and/or MT 2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT 1 and/or MT 2 receptor agonistic activity and has a low ability of migrating into the central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT 1 and/or MT 2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.